medigraphic.com

2012, Number 2

<< Back Next >>

Rev Hematol Mex 2012; 13 (2)

The Role of Nucleophosmin (NPM1) in Myeloid Malignancies

Noguera NI, Garza PE, Lo-Coco F

Language: Spanish
References: 62
Page: 65-73
PDF size: 203.96 Kb.


ABSTRACT

Nucleophosmin (NPM1) is a ubiquitously expressed phosphoprotein that belongs to the nucleoplasmin family of chaperones. NPM1 is mainly localized in the nucleolus, and continuously shuttles between the nucleus and the cytoplasm. A high number of proteins have been described to interact with NPM1. NPM1 play a relevant role in diverse cellular functions, including, centrosome duplication, ribosome biogenesis, response to stress and ADN repair. Alterations of the NPM1 gene have been reported in anaplastic non Hodgkin’s lymphoma and acute myeloid leukemia (AML).
AML carrying nucleophosmin mutations (also referred to as NPMc+) displays distinct molecular and clinical–pathological features that led to its inclusion as a provisional entity in the 2008 WHO classification of myeloid neoplasms. Here, we discuss the role of NPM1 in myeloid malignancies focusing on i) involvement in AML pathogenesis; ii) diagnosis; iii) prognostic significance; iv) minimal residual disease monitoring and v) its potential as a target for tailored therapy.


REFERENCES

  1. Grisendi S, Mecucci C, Falini B, Pandolfi PP. Nucleophosmin and cancer. Nat Rev Cancer 2006;6:493-505

  2. Ruggero D, Pandolfi PP. Does the ribosome translate cancer? Nat Rev Cancer 2003;3:179-192

  3. Ye K. Nucleophosmin/B23, a multifunctional protein that can regulate apoptosis. Cancer Biol Ther 2005;4(9):918-23.

  4. Colombo E, Martinelli P, Zamponi R, Shing DC, Bonetti P, Luzi L, et al. Delocalization and destabilization of the Arf tumor suppressor by the leukemia-associated NPM mutant. Cancer Res 2006; 66(6):3044-50.

  5. Okuda M, Horn HF, Tarapore P, Tokuyama Y, Smulian AG, Chan PK, et al. Nucleophosmin/B23 is a target of CDK2/cyclin E in centrosome duplication. javascript:AL_get(this, ‘jour’, ‘Cell.’); Cell 2000;103(1):127-40.

  6. Tanaka M, Sasaki H, Kino I, Sugimura T, Terada M. Genes preferentially expressed in embryo stomach are predominantly expressed in gastric cancer. Cancer Res 1992;52(12):3372-7.

  7. Nozawa Y, Van Belzen N, Van der Made AC, Dinjens WN, Bosman FT. Expression of nucleophosmin/B23 in normal and neoplastic colorectal mucosa. J Pathol 1996;178(1):48-52.

  8. Bernard K, Litman E, Fitzpatrick JL, Shellman YG, Argast G, Polvinen K, et al. Functional proteomic analysis of melanoma progression. Cancer Res 2003;63(20):6716-25

  9. Falini B, Nicoletti I, Bolli N, Martelli MP, Liso A, Gorello P, et al. Translocations and mutations involving the nucleophosmin (NPM1) gene in lymphomas and leukemias. Haematologica 2007;92(4):519-32. Review.

  10. Meani N, Alcalay M. Role of nucleophosmin in acute myeloid leukemia. Expert Rev Anticancer Ther 2009;(9):1283-94.

  11. Okazuka K, Masuko M, Seki Y, Hama H, Honma N, Furukawa T, et al. Successful all-trans retinoic acid treatment of acute promyelocytic leukemia in a patient with NPM/RAR fusion. Int J Hemathol 2007;86(3):246-249.

  12. Sportoletti P, Grisendi S, Majid SM, Cheng K, Clohessy JG, et al. Npm1 is a haploinsufficient suppressor of myeloid and lymphoid malignancies in the mouse. Blood 2008;111(7) 3859-3862.

  13. Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, et al. Cytoplasmic Nucleophosmin (NPM) Identifies a Subtype of Acute Myelogenous Leukemia with a Normal Karyotype and NPM1 Gene Mutations. New Engl Med 2005;352:254-266.

  14. Falini B, Mecucci C, Saglio G, Lo Coco F, Diverio D, et al. NPM1 mutations and cytoplasmic nucleophosmin are mutually exclusive of recurrent genetic abnormalities: a comparative analysis of 2562 patients with acute myeloid leukemia. Haematologica 2008;93(3):439-442.

  15. Braoudaki M, Papathanassiou C, Katsibardi K, Tourkadoni N, Karamolegou K, et al. The frequency of NPM1 mutations in childhood acute myeloid leukemia. J Hematol Oncol 2010;3:41

  16. Falini B. Acute myeloid leukemia with mutated nucleophosmin (NPM1): molecular, pathological, and clinical features. Cancer Treat Res 2010;145:149-168.

  17. Falini B, Martelli MP, Bolli N, Sportoletti P, Liso A, Tiacci E, et al. Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity? Blood 2011;117(4):1109-1120.

  18. Okuwaki M. The structure and functions of NPM1/Nucleophsmin/ B23, a multifunctional nucleolar acidic protein. J Biochem 2008;143(4):441-448.

  19. Hingorani K, Szebeni A, Olson MO. Mapping the functional domains of nucleolar protein B23. J Biol Chem 2000;275(32):24451-24457.

  20. Tokuyama Y, Horn HF, Kawamura K, Tarapore P, Fukasawa K. Specific phosphorylation of nucleophosmin on Thr(199) by cyclin-dependent kinase 2-cyclin E and its role in centrosome duplication. J Biol Chem 2001; 276(24):21529-21537.

  21. Liu X, Liu Z, Jang SW, Shinmura K, Kang S, Dong S, et al. Sumoylation of nucleophosmin/B23 regulates its subcellular localization, mediating cell proliferation and survival. Proc Natl Acad Sci US A. 2007; 104(23):9679-9684.

  22. Shandilya J, Swaminathan V, Gadad SS, Choudhari R, Kodaganur GS, Kundu TK. Acetylated NPM1 localizes in the nucleoplasm and regulates transcriptional activation of genes implicated in oral cancer manifestation. Mol Cell Biol 2009;18:5115-5127.

  23. Weber JD, Jeffers JR, Rehg JE, Randle DH, Lozano G, Roussel MF, et al. p53-independent functions of the p19(ARF) tumor suppressor. Genes Dev 2000;14:2358-65.

  24. Weber JD, Taylor LJ, Roussel MF, Sherr CJ, Bar-Sagi D. Nucleolar Arf sequesters Mdm2 and activates p53. Nat Cell Biol 1999;1: 20-6.

  25. Bonetti P, Davoli T, Sironi C, Amati B, Pelicci PG, Colombo E. Nucleophosmin and its AML-associated mutant regulate c-Myc turnover through Fbw7 gamma. J Cell Biol 2008;182(1):19-26.

  26. Luo H, Q Li J, O’ Neal, Kreisel F, Le Beau MM, Tomasson MH. c-Myc rapidly induces acute myeloid leukemia in mice without evidence of lymphoma-associated antiapoptotic mutations. Blood 2005;106:2452-2461.

  27. Cheng K, Grisendi S, Clohessy JG, Majid S, Bernardi R, et al. The leukemia-associated cytoplasmic nucleophosmin mutant is an oncogene with paradoxical functions: Arf inactivation and induction of cellular senescence. Oncogene 2007;26:7391-400.

  28. Wanzel M, Russ AC, Kleine-Kohlbrecher D, Colombo E, Pelicci PG, Eilers M. A ribosomal protein L23-nucleophosmin circuit coordinates Mizl function with cell growth. Nat Cell Biol 2008;10:1051-1061.

  29. Falini B, Bolli N, Liso A, Martelli MP, Mannucci R, Pileri S, et al. Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: molecular basis and clinical implications. Leukemia 2009;23(10):1731-1743.

  30. Sportoletti P, Grisendi S, Majid SM, Cheng K, Clohessy JG, Viale A, et al. Npm1 is a haploinsufficient suppressor of myeloid and lymphoid malignancies in the mouse. Blood 2008;111(7):3859-3862.

  31. Rau R, Brown P. Nucleophosmin (NPM1) mutations in adult and childhood acute myeloid leukaemia: towards definition of a new leukaemia entity. Hematol Oncol 2009;27(4):171-181.

  32. Albiero E, Madeo D, Bolli N, Giaretta I, Bona ED, Martelli MF, et al. Identification and functional characterization of a cytoplasmic nucleophosmin leukaemic mutant generated by a novel exon-11 NPM mutation. Leukemia 2007;21(5):1099-1103.

  33. Brown P, McIntyre E, Rau R, Meshinchi S, Lacayo N, Dahl G, et al. The incidence and clinical significance of nucleophosmin mutations in childhood AML Blood 2007;110(3):979-985.

  34. Hollink IH, Zwaan CM, Zimmermann M, Arentsen-Peters TC, Pieters R, Cloos J, et al. Favorable prognostic impact of NPM1 gene mutations in childhood acute myeloid leukemia, with emphasis on cytogenetically normal AML. Leukemia 2009;23(2):262-270.

  35. Thiede C, Creutzig E, Reinhardt D, Ehninger G, Creutzig U. Different types of NPM1 mutations in children and adults: evidence for an effect of patient age on the prevalence of the TCTG-tandem duplication in NPM1-exon 12. Leukemia 2007;21(2):366-367.

  36. Noguera NI, Ammatuna E, Zangrilli D, Lavorgna S, Divona M, Buccisano F, et al. Simultaneous detection of NPM1 and FLT3-ITD mutations by capillary electrophoresis in acute myeloid leukemia Leukemia 2005;19(8):1479-82. Erratum in: Leukemia. 2007 May;21(5):1134.

  37. Lin LI, Lin TC, Chou WC, Tang JL, Lin DT, Tien HF. A novel fluorescence-based multiplex PCR assay for rapid simultaneous detection of CEBPA mutations and NPM mutations in patients with acute myeloid leukemias. Leukemia. 2006;20(10):1899-1903

  38. Schnittger S, Schoch C, Kern W, Mecucci C, Tschulik C, Martelli MF, et al. Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood. 2005;106(12):3733-3739.

  39. B. Falini, Gionfriddo I, Cecchetti F, Ballanti S, Pettirossi V, Martelli MP. Acute myeloid leukemia with mutates nucleophosmin (NPM1): any hope for a targeted therapy? Blood Reviews 2011;25:247-257.

  40. Gorello P, Cazzaniga G, Alberti F, Dell’Oro MG, Gottardi E, Specchia G, et al. Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations. Leukemia 2006;20(6):1103-1108.

  41. Ottone T, Ammatuna E, Lavorgna S, Noguera NI, Buccisano F, Venditti A, et al. Lo-Coco F. An allele-specific rt-PCR assay to detect type A mutation of the nucleophosmin-1 gene in acute myeloid leukemia. J Mol Diagn. 2008;10(3):212-6.

  42. Calvo KL, Ojeda MJ, Ammatuna E, Lavorgna S, Ottone T, Targovnik HM, et al. Detection of the nucleophosmin gene mutations in acute myelogenous leukemia through RT-PCR and polyacrylamide gel electrophoresis. Eur J Haematol. 2009;82(1):69-72.

  43. Santamaría CM, Chillón MC, García-Sanz R, Pérez C, Caballero MD, Ramos F, et al. Molecular stratification model for prognosis in cytogenetically normal acute myeloid leukemia. Blood 2009;114:148

  44. Marcucci G, Maharry K, Whitman SP, Vukosavljevic T, Paschka P, Langer C, et al. High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B Study. J Clin Oncol 2007;25(22):3337-43.

  45. Schlenk RF, Döhner K, Krauter J, Fröhling S, Corbacioglu A, Bullinger L, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008;358(18):1909-18.

  46. Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH ,et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 2010;116(3):354-65.

  47. Schneider F, Hoster E, Unterhalt M, Schneider S, Dufour A, Benthaus T ,et al. The FLT3ITD mRNA level has a high prognostic impact in NPM1 mutated, but not in NPM1 unmutated AML with a normal karyotype. Blood 2012;Feb 28, Epub.

  48. Sockel K, Wermke M, Radke J, Kiani A, Schaich M, Bornhäuser M, et al. Minimal residual disease-directed preemptive treatment with azacitidine in patients with NPM1-mutant acute myeloid leukemia and molecular relapse. Haematologica 2011;96(10):1568-70. Epub 2011 Jul 12.

  49. Haferlach T, Bacher U, Alpermann T, Haferlach C, Kern W, Schnittger S. Amount of bone marrow blasts is strongly correlated to NPM1 and FLT3-ITD mutation rate in AML with normal karyotype. Leukemia Research 2012;36:51-58

  50. Becker H, Marcucci G, Maharry K, Radmacher MD, Mrózek K, Margeson D, et al. Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNAexpression signatures: a Cancer and Leukemia Group B study. J Clin Oncol 2010;28(4):596

  51. Döhner Konstanze, Schlenk FS, Habdank M, Scholl C, Rücker FG, Corbacioglu A, et al. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood 2005;106(12):3740-3748.

  52. Anensen N, Hjelle SM, Van Belle W, Haaland I, Silden E, Bourdon JC, et al. Correlation analysis of p53 protein isoforms with NPM1/FLT3 mutations and therapy response in acute myeloid leukemia. Oncogene 2011:1-13 online publication.

  53. Perera Y, Farina HG, Gil G. Anticancer peptide CIGB-300 binds to nucleophosmin/B23, impairs its CK2-mediated phosphorylation, and leads to apoptosis through its nucleolar disassembly activity. Mol Cancer Ther 2009;8:1189-1196.

  54. Chevallier P, Prebet T, Pigneux A, Hunault M, Delaunay J, Perry F, et al. Influence of NPM1 and FLT3-ITD status on outcome in relapsed/refractory AML patients receiving salvage therapy including gemtuzumab ozogamicin. Leukemia 2010;24:467-469.

  55. Grisendi S, Bernardi R, Rossi M, Cheng K, Khandker L, Manova K, et al. Role of nucleophosmin in embrionic development and tumorigenesis. Nature 2005;437:147-153.

  56. Ebert B. Molecular Dissection of the 5q Deletion in Myelodyaplastic Syndrome. Seminars in Oncology 2011;38(5):621-626.

  57. Ammatuna E, Panetta P, Agirre X, Ottone T, Lavorgna S, Calasanz MJ, et al. NPM1 gene deletions in myelodysplastic syndromes with 5q- and complex karyotype. Haematologica 2011;96(5):784-785.

  58. Douet-Guilbert N, De Braekeleer E, Basinko A, Guéganic N, Bovo C, Le Bris MJ, et al. Molecular characterization of deletions of the long arm of chromosome 5 (del(5q)) in 94 MDS/AML patient. Leukemia 2012;1-3 online publication.

  59. La Starza R, Matteucci C, Gorello P, Brandimarte L, Pierini V, Crescenzi B, et al. NPM1 deletion is associated with gross chromosomal rearrangement in leukemia. PLoS ONE 2010; 5(9):e12855.

  60. Pellagati A, Cazzola M, Giagounidis A, Perry J, Malcovati L, Della Porta MG, et al. Marked down-regulation of nucleophosmin-1 is associated with advanced del(5q) myelodysplastic syndrome. Br J Haematol 2011:155;272-274.

  61. Bakarat F, Luthra R, Yin C, Barkoh BA, Hai S, Jamil W, et al. Detection of Nucleophosmin 1 Mutations by Quantitative Real-Time Polymerase Chain Reaction versus Capillary Electrophoresis. Arch Pathol Lab Med 2011;135:994-1000.

  62. Patel JP, Gönen M, Figueroa ME, Fernandez H, et al. Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia. N Engl J Med 2012;366(12):1079-89.




2020     |     www.medigraphic.com